c.marchetti
TL2 Moderator · Dijon
Contributes reviews on supplier material. Based in Dijon.
Joined 26 August 2025 · last posted 5d
77 posts, newest first. Showing up to 150.
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #117 · Analytics › Home & field testing · 23 Jul 2026 · 1 like Immunoassay limitations: tests that use antibodies have cross-reactivity limitations. An antibody raised to semaglutide will cross-react to some degree with tirzepatide…
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #89 · Sourcing › Independent verification · 13 Jul 2026 · 5 likes Cost and turnaround: different services have different pricing and turnaround times. Janoshik's turnaround is weeks by mail; VendorInvestigate documentation review is…
-
Seven-day rolling means and why weekly readings mislead Replied, post #20 · Outcomes › Progress reports · 12 Jul 2026 · 28 likes Exercise volume changes: increasing exercise intensity or duration can mask weight loss (muscle gain) on the scale. Noting exercise changes when reporting weight helps…
-
Coming back to: How much context is too much context in a first post? Replied, post #6 · Start Here › How to Ask · 7 Jul 2026 · 2 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Common supplements people ask about, assessed one at a time Replied, post #5 · Practice › Interactions · 2 Jul 2026 · 5 likes Coming back to post #3, because the follow-up matters more than the original answer. Having read the exchange above, I think I was wrong earlier in this topic and I…
-
Dizziness on standing: the ordinary explanation first — one year on Replied, post #11 · Nutrition & Training › Hydration & electrolytes · 22 Jun 2026 · 29 likes Picking up post #8: that is the part I would want checked first. Water intoxication: drinking excessive water (more than a few liters per day for extended time) without…
-
Alcohol: what is documented and what is folklore Replied, post #71 · Practice › Interactions · 22 Jun 2026 · 5 likes On post #67 — agreed on the reasoning, with one qualification. SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to…
-
A reconstituted vial's beyond-use date and the reasoning behind common figures Replied, post #19 · Practice › Storage & stability · 2 Jun 2026 · 26 likes Visual inspection: if a solution is visibly cloudy, discoloured, or contains particles, those are red flags. Faint opalescence or minor colour shift may be normal but…
-
What changed in 2026, by region — does this still hold? Replied, post #12 · Access › International · 31 May 2026 · 1 like Worth separating two things that post #8 runs together. Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates…
-
Second pass at: What a 2 ppm match establishes, and what it does not Replied, post #20 · Analytics › Mass spectrometry · 28 May 2026 · 8 likes Resolution: "high resolution" commonly means
-
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #92 · Compounds › Tirzepatide · 26 May 2026 · 0 likes The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how…
-
Specificity, linearity, accuracy, precision, range, robustness — with real criteria Replied, post #15 · Analytics › Method validation · 8 May 2026 · 8 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
How to ask about something you suspect is a bad idea Replied, post #85 · Start Here › How to Ask · 6 May 2026 · 3 likes Worth separating two things that post #81 runs together. Two things before anyone answers the substance. First, the context in the first post is clear and specific.…
-
[2026 update] What a purity-only report leaves out Replied, post #101 · Sourcing › Independent verification · 23 Apr 2026 · 8 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
The headache that turns out to be dehydration — the long version Replied, post #23 · Nutrition & Training › Hydration & electrolytes · 18 Apr 2026 · 4 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
[2026 update] Area percent versus weight percent: the confusion that causes most arguments Replied, post #28 · Analytics › HPLC & UHPLC · 9 Apr 2026 · 16 likes I read post #26 twice before replying, because I had assumed the opposite. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write…
-
[2026 update] Composite endpoints and the component doing the work Replied, post #58 · Evidence › Trials · 5 Apr 2026 · 0 likes Picking up post #55: that is the part I would want checked first. Open-label design: unblinded trials admit expectation effects. For weight-loss trials where one arm…
-
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #23 · Evidence › Journal club · 4 Apr 2026 · 1 like Session format: read the paper before posting. The discussion is much better when everyone has. Start with the estimand and population, then methods, then results, then…
-
Blind submission and why it changes minds — the long version Replied, post #7 · Sourcing › Independent verification · 2 Apr 2026 · 10 likes This follows post #4 rather than contradicting it. I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The…
-
Packaging that arrived damaged: documenting it properly — a second dataset Replied, post #63 · Sourcing › Logistics · 27 Mar 2026 · 7 likes Packaging integrity on arrival: if a parcel arrives with compromised packaging, that is evidence of a handling problem in transit. The contents may or may not be…
-
Five questions in one post gets you one answer — how to split them Replied, post #32 · Start Here › How to Ask · 16 Mar 2026 · 23 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Why the absence of controlled human data on BPC-157 matters more than people admit Started this topic · Compounds › Repair & healing peptides · 13 Mar 2026 · 37 likes Why the absence of controlled human data on BPC-157 matters more than people admit — that is the question, and I have not found it answered plainly anywhere I have…
-
Angle of injection and whether 90 degrees is always right Replied, post #102 · Practice › Administration · 18 Feb 2026 · 0 likes Picking up post #99: that is the part I would want checked first. Leak-back after withdrawal: a small amount of liquid on the skin after withdrawal is ordinary. Whether…
-
Residual solvents and scavengers: what is looked for — what changed since Replied, post #7 · Analytics › Impurities & related substances · 13 Feb 2026 · 17 likes Acetate content: counter-ion content. Trifluoroacetate or acetate from the salt form of the peptide. Affects mass calculations and should be stated on a complete…
-
Interpreting a result that disagrees with the supplier's certificate Replied, post #120 · Sourcing › Independent verification · 13 Feb 2026 · 0 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — a second dataset Replied, post #24 · Sourcing › Independent verification · 7 Feb 2026 · 7 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Second pass at: What pooling buys you and what it destroys Replied, post #13 · Evidence › Meta-analyses · 28 Jan 2026 · 17 likes On post #9 — agreed on the reasoning, with one qualification. Publication bias: what did not get published? Small studies with negative results are less likely to be…
-
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Replied, post #22 · Clinical › Special populations · 21 Jan 2026 · 7 likes post #21 is right about the mechanism and I think understates the practical bit. Hypoglycemia risk: in people already on insulin or sulfonylureas, adding a GLP-1…
-
Pharmacy supply in the UK and the questions you will be asked Started this topic · Regional › UK & Ireland · 31 Dec 2025 · 2 likes On the subject in the title: Pharmacy supply in the UK and the questions you will be asked Working notes rather than a conclusion. A coverage question with the…
-
Research-use-only labelling: what it means and what it does not Replied, post #75 · Sourcing › Regulatory · 20 Dec 2025 · 4 likes Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a…
-
Second pass at: Metformin co-administration and additive GI effects Replied, post #13 · Practice › Interactions · 2 Dec 2025 · 0 likes I read post #11 twice before replying, because I had assumed the opposite. Alcohol: no absolute contraindication but it raises gastrointestinal irritation risk and this…
-
Sequence verification for an obscure compound: how it is done — what changed since Replied, post #38 · Compounds › Other compounds · 23 Nov 2025 · 21 likes post #37 answers the question as asked. The question underneath it is different. Thank you for the correction. I have edited my earlier post with a note rather than…
-
[2026 update] What steady state means for the decision to escalate Replied, post #22 · Practice › Dosing & titration · 6 Nov 2025 · 26 likes Picking up post #19: that is the part I would want checked first. Dose equivalence between different incretin analogues is a weak concept. The molecules differ in…
-
Second pass at: Programming during a large energy deficit Replied, post #68 · Nutrition & Training › Resistance training · 5 Nov 2025 · 0 likes Programming while losing weight quickly: realistic expectations are crucial. Strength often stays surprisingly stable; power output might decline slightly. Expecting…
-
A 10 mg vial reconstituted three different ways, compared — the long version Replied, post #155 · Practice › Reconstitution · 30 Oct 2025 · 7 likes Worth separating two things that post #151 runs together. How much of the diluent volume the powder itself displaces: for a small peptide vial, the powder volume is…
-
Pooling trials with different estimands — what changed since Replied, post #43 · Evidence › Meta-analyses · 28 Oct 2025 · 3 likes Number needed to treat from a meta-analysis: can be computed from the pooled estimate if the baseline risk is specified. More interpretable than pooled relative effects.
-
Publishing an inconvenient result: a case study — the long version Replied, post #16 · Sourcing › Independent verification · 22 Oct 2025 · 32 likes On post #12 — agreed on the reasoning, with one qualification. Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a…
-
Follow-up: Subcutaneous absorption kinetics and site differences Replied, post #5 · Pharmacology › Pharmacokinetics · 12 Oct 2025 · 15 likes SNAC (the oral bioavailability enhancer): sodium N-(8-[2-hydroxybenzoyl]amino) caprylate transiently raises gastric pH and promotes absorption. Without it, oral…
-
Compounds this community declines to help with, and why Replied, post #70 · Compounds › Other compounds · 6 Oct 2025 · 6 likes This follows post #67 rather than contradicting it. Compounds this community declines to help with, and why: there are specifics in the guidelines and they are not…
-
Second pass at: The mass-error checker and its intended scope Replied, post #29 · Data & Tools › Calculators · 2 Oct 2025 · 1 like Why calculators are not medical advice: they do arithmetic. Medical decisions are not arithmetic. A calculator that says a certain dose is "compatible with" a certain…
-
Cagrilintide's dosing interval and the pharmacokinetics behind it Replied, post #25 · Compounds › Cagrilintide & amylin analogues · 2 Oct 2025 · 9 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Follow-up: History of disordered eating and why it changes the conversation Replied, post #53 · Clinical › Special populations · 3 Aug 2025 · 31 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Counter-ion content and its effect on measured mass Replied, post #98 · Analytics › Mass spectrometry · 21 Jul 2025 · 0 likes Tandem mass spectrometry: MS/MS fragments the molecular ion and uses fragment masses to confirm identity and detect modifications. A simple identity confirmation by…
-
Interim analyses and stopping rules — does this still hold? Replied, post #27 · Evidence › Trials · 2 Jul 2025 · 15 likes post #26 answers the question as asked. The question underneath it is different. Surrogate endpoints: an endpoint that is not the outcome that matters but is measured…
-
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #73 · Compounds › Retatrutide · 2 Jul 2025 · 4 likes I read post #71 twice before replying, because I had assumed the opposite. Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not…
-
Hepatic steatosis: what the MASH trial evidence supports Replied, post #73 · Clinical › Comorbidities · 24 Jun 2025 · 32 likes Comorbidity control: if a comorbidity (high blood pressure, high lipids) is not adequately controlled, the decision about adding compounds in this class depends on the…
-
A side-effect grading scheme this community uses, and its limits Replied, post #2 · Practice › Side effects · 16 Jun 2025 · 4 likes On the opening post — agreed on the reasoning, with one qualification. Lean mass loss: the rate of lean tissue loss depends on protein intake, resistance training…
-
Second pass at: Trial registration and comparing the protocol with the paper Replied, post #16 · Evidence › Trials · 6 Jun 2025 · 14 likes Picking up post #13: that is the part I would want checked first. Risk of bias: structured appraisal of internal validity. Key things to assess: randomisation method…
-
What this community means by "a source", in practical terms Started this topic · Start Here › Welcome · 5 Jun 2025 · 3 likes Asking directly, because I could not find a straight answer: What this community means by "a source", in practical terms Question in the title. Context below, and I…
-
Coming back to: Getting a referral rather than a refusal Replied, post #34 · Clinical › Prescriber conversations · 5 Jun 2025 · 22 likes This follows post #31 rather than contradicting it. I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The…
-
Second pass at: Semaglutide and alcohol: what is actually documented Replied, post #8 · Compounds › Semaglutide · 31 May 2025 · 17 likes Is there a ceiling dose beyond which the effect plateaus? The trials did not study that because they stopped at 2.4 mg. Some people report trying higher doses, but…
-
Follow-up: What other technical communities get right that we do not Replied, post #111 · Lounge › Off topic · 27 May 2025 · 3 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Ipamorelin selectivity claims and where they came from — a second dataset Replied, post #3 · Compounds › Secretagogues & GH axis · 16 May 2025 · 0 likes CJC-1295 with and without DAC: the version with a drug affinity complex binds albumin covalently and persists for days. The version without it does not persist.…
-
DXA precision and the least significant change for lean mass — the long version Replied, post #17 · Outcomes › Body composition · 8 May 2025 · 0 likes I read post #15 twice before replying, because I had assumed the opposite. Ultrasound: thickness of subcutaneous fat at specific sites. Less standardised than DXA and…
-
[2026 update] Dose numbers across compounds are not on the same scale Replied, post #12 · Practice › Dosing & titration · 30 Apr 2025 · 14 likes post #11 answers the question as asked. The question underneath it is different. Splitting a weekly dose in two: the pharmacokinetic argument against is that you want…
-
Coming back to: Checking someone else's arithmetic: a worked example thread Started this topic · Practice › Reconstitution · 11 Apr 2025 · 0 likes Posting this under the heading it deserves: Checking someone else's arithmetic: a worked example thread Everything below is what sits behind that. Practical question…
-
Retatrutide dose escalation in the published trials Replied, post #118 · Compounds › Retatrutide · 11 Apr 2025 · 2 likes On post #114 — agreed on the reasoning, with one qualification. Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood…
-
Anxiety in the first weeks: drug, situation, or both Replied, post #71 · Wellbeing › Mental health · 6 Apr 2025 · 32 likes Social and relationship impacts: weight change affects how others perceive and interact with a person. Those impacts are real and can be psychologically significant.
-
What the published dose-response for semaglutide actually looks like above 2.4 mg — a… Replied, post #101 · Compounds › Semaglutide · 14 Mar 2025 · 23 likes Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time,…
-
Hepatic steatosis: what the MASH trial evidence supports Started this topic · Clinical › Comorbidities · 9 Mar 2025 · 13 likes Hepatic steatosis: what the MASH trial evidence supports — setting out what I have, and where I think it stops being reliable. Asking about a population rather than…
-
Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold? Replied, post #47 · Evidence › Journal club · 25 Feb 2025 · 0 likes PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not efficacy. Non-inferiority for safety was met. The trial was not designed to…
-
Coming back to: Official shortage notices and what they authorise Replied, post #28 · Access › Shortages · 19 Feb 2025 · 0 likes post #27 is right about the mechanism and I think understates the practical bit. Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are…
-
Why mass spectrometry cannot tell you about an epimer Replied, post #60 · Analytics › Mass spectrometry · 17 Feb 2025 · 29 likes Electrospray ionisation produces multiply charged ions. For a 4 kDa peptide you expect mostly 2+, 3+, and 4+ charge states. Reading an electrospray spectrum means…
-
Reading a chromatogram someone posted without axes Replied, post #2 · Analytics › HPLC & UHPLC · 8 Feb 2025 · 13 likes Peak purity: a diode-array detector records a spectrum at every time point. If a peak contains two co-eluting species with different spectra, the spectrum changes…
-
Oxidation pathways for methionine and tryptophan Replied, post #13 · Analytics › Impurities & related substances · 26 Dec 2024 · 31 likes Deamidation at asparagine and glutamine: adds 1 approximately. Frequently appears as a close-eluting pair. It is a chemical modification that occurs during storage.
-
Turnaround times and what they mean for a decision — one year on Replied, post #24 · Sourcing › Independent verification · 24 Dec 2024 · 0 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Second pass at: Choosing a concentration on purpose rather than by accident Replied, post #24 · Practice › Reconstitution · 24 Nov 2024 · 0 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Replied, post #52 · Compounds › Tirzepatide · 24 Nov 2024 · 9 likes On post #48 — agreed on the reasoning, with one qualification. Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means…
-
[2026 update] Step therapy requirements and how to satisfy them Replied, post #38 · Access › Insurance & coverage · 23 Nov 2024 · 32 likes Generic versus brand: most of these compounds do not have generic versions yet. Once they do, formulary coverage and pricing will shift.
-
Coming back to: Preparing for an appointment: one page, three questions Replied, post #106 · Clinical › Prescriber conversations · 23 Nov 2024 · 9 likes Understanding stopping rules: what would prompt stopping the compound? Adverse effect, lack of benefit after a defined time, or other reasons? Knowing in advance is…
-
Second pass at: Gauge and length selection for subcutaneous injection Replied, post #3 · Devices › Syringes & needles · 20 Nov 2024 · 26 likes Reading units correctly: look at the marking from the side, not from above or below. The bottom of the plunger tip is the reading. Parallax error (wrong angle) is a…
-
When "no data" is the complete and final answer Replied, post #22 · Compounds › Other compounds · 16 Nov 2024 · 0 likes Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or…
-
Anxiety in the first weeks: drug, situation, or both Replied, post #10 · Wellbeing › Mental health · 22 Oct 2024 · 0 likes Mood and anxiety: mood changes and anxiety are reported by some people. Baseline mental health status matters for risk. Someone with a history of depression should plan…
-
Splitting a vial for two laboratories: how to do it without ruining both — what changed… Replied, post #95 · Sourcing › Independent verification · 29 Sep 2024 · 0 likes Coming back to post #93, because the follow-up matters more than the original answer. Blind sampling: submitting without the laboratory or seller knowing the source…
-
Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #47 · Evidence › Journal club · 18 Sep 2024 · 22 likes PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not efficacy. Non-inferiority for safety was met. The trial was not designed to…
-
Revisiting: How to bring a laboratory report to an appointment usefully Replied, post #7 · Clinical › Bloodwork · 3 Sep 2024 · 1 like Time of day: some biomarkers vary across the day. Cortisol in the morning differs from cortisol in the evening. Comparing results from different times of day is…
-
The topic list is dense — is that deliberate? Replied, post #10 · Meta › Site feedback · 2 Aug 2024 · 0 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…